Skip to content

Pirtobrutinib significantly improves PFS in patients with treatment-naïve CLL/SLL
“Promising” early-phase results seen with KLN-1010, an off-the-shelf in vivo CAR-T for myeloma
Teclistamab plus daratumumab improves survival compared with SOC triplet therapy in relapsed/refractory MM
Phase 3 study finds fixed-duration treatment non-inferior to continuous treatment in CLL
Extended MorningSun study results show ‘promising’ survival with subcutaneous mosunetuzumab

Join SOHO

Follow Us :

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Meeting News
Multimedia
- Roundtable Discussions
  - MDS Roundtable
  - MPN Roundtable
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

“Promising” early-phase results seen with KLN-1010, an off-the-shelf in vivo CAR-T for myeloma

Cellular Therapy

“Promising” early-phase results seen with KLN-1010, an off-the-shelf in vivo CAR-T for myeloma

Leukemia

“Promising” early-phase results seen with KLN-1010, an off-the-shelf in vivo CAR-T for myeloma

Lymphoma

“Promising” early-phase results seen with KLN-1010, an off-the-shelf in vivo CAR-T for myeloma

Multiple Myeloma

“Promising” early-phase results seen with KLN-1010, an off-the-shelf in vivo CAR-T for myeloma

Myelodysplastic Syndromes

“Promising” early-phase results seen with KLN-1010, an off-the-shelf in vivo CAR-T for myeloma

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

December 9, 2025

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Meeting News
Multimedia
- Roundtable Discussions
  - MDS Roundtable
  - MPN Roundtable
- Video Interviews
Subscribe

SOHO Insider Hem/Onc Library Multiple Myeloma

Multiple Myeloma News

Multiple Myeloma News

“Promising” early-phase results seen with KLN-1010, an off-the-shelf in vivo CAR-T for myeloma

by Kerri Fitzgerald
December 9, 2025
0 Comments

Time to phase 3 symbol. Concept word Phase 1 2 3 on wooden block. Businessman hand. Beautiful grey table grey background. Business planning and time to phase 3 concept. Copy space.

Multiple Myeloma News

Teclistamab plus daratumumab improves survival compared with SOC triplet therapy in relapsed/refractory MM

by Kerri Fitzgerald
December 9, 2025
0 Comments

pen check

ASH 2025 Multiple Myeloma News

Pre-apheresis lenalidomide improves T-cell fitness in patients with myeloma undergoing transplant

by Kerri Fitzgerald
December 6, 2025
0 Comments

ASH 2025 Multiple Myeloma News

Investigational bispecific antibody shows ‘encouraging’ antitumor activity in relapsed/refractory myeloma

by Kerri Fitzgerald
December 6, 2025
0 Comments

Gloves

Multiple Myeloma News

Extramedullary disease in MM associated with severe toxicities following BCMA-targeted CAR T-cell therapy

by Leah Sherwood
December 2, 2025
0 Comments

up close shot of a doctor

Multiple Myeloma News SOHO 2025 Multiple Myeloma News

Dr. Sundar Jagannath defines ‘cure’ in multiple myeloma

by SOHO Insider Editors
November 30, 2025
0 Comments

IV therapy; CAR-T

Multiple Myeloma News

FDA adds enterocolitis risk warning to approved CAR-T cell therapy

by SOHO Insider Editors
November 28, 2025
0 Comments

SOHO Insider

Multiple Myeloma Video Interviews

Dr. Abdallah on blenrep combo approval in relapsed myeloma

by SOHO Insider Editors
November 21, 2025
0 Comments

SOHO Insider podcast

Multiple Myeloma SOHO Insider Podcast

Does the future of myeloma treatment belong to trispecific antibodies?

by Leah Sherwood
November 18, 2025
0 Comments

FDA Green light

Multiple Myeloma

FDA grants 510(k) clearance to multiple myeloma diagnostic platform

by Leah Sherwood
November 13, 2025
0 Comments

1
2
3
...
7

Top Categories

Cellular Therapy

13

Leukemia

71

Lymphoma

67

Multiple Myeloma

63

Myelodysplastic Syndromes

24

Myeloproliferative Neoplasms

12

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

FDA grants 510(k) clearance to multiple myeloma diagnostic platform

Cellular Therapy

FDA grants 510(k) clearance to multiple myeloma diagnostic platform

Leukemia

FDA grants 510(k) clearance to multiple myeloma diagnostic platform

Lymphoma

FDA grants 510(k) clearance to multiple myeloma diagnostic platform

Multiple Myeloma

FDA grants 510(k) clearance to multiple myeloma diagnostic platform

Myelodysplastic Syndromes

FDA grants 510(k) clearance to multiple myeloma diagnostic platform

Myeloproliferative Neoplasms

Subscribe

Recent Posts

Pirtobrutinib significantly improves PFS in patients with treatment-naïve CLL/SLL

“Promising” early-phase results seen with KLN-1010, an off-the-shelf in vivo CAR-T for myeloma

Time to phase 3 symbol. Concept word Phase 1 2 3 on wooden block. Businessman hand. Beautiful grey table grey background. Business planning and time to phase 3 concept. Copy space.

Teclistamab plus daratumumab improves survival compared with SOC triplet therapy in relapsed/refractory MM

Copyright © 2025 Society of Hematologic Oncology, All rights reserved.